{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T11:44:09Z","timestamp":1773920649591,"version":"3.50.1"},"reference-count":57,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,12]]},"DOI":"10.1097\/qco.0b013e328359eff2","type":"journal-article","created":{"date-parts":[[2012,11,9]],"date-time":"2012-11-09T07:11:24Z","timestamp":1352445084000},"page":"695-702","source":"Crossref","is-referenced-by-count":31,"title":["Recent advances in development of amphotericin B formulations for the treatment of visceral leishmaniasis"],"prefix":"10.1097","volume":"25","author":[{"given":"Abeer H.A.","family":"Mohamed-Ahmed","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen","family":"Brocchini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simon L.","family":"Croft","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R2-12-20210205","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1038\/nrmicro1748z","article-title":"Visceral leishmaniasis: what are the needs for diagnosis, treatment and control.","volume":"5","author":"Chappuis","year":"2007","journal-title":"Nat Rev Microbiol"},{"key":"R3-12-20210205","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1111\/j.1469-0691.2011.03630.x","article-title":"Leishmaniasis chemotherapy -- challenges and opportunities.","volume":"17","author":"Croft","year":"2011","journal-title":"Clin Microbiol Infect"},{"key":"R4-12-20210205","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1056\/NEJMoa0903627","article-title":"Single-dose liposomal amphotericin B for visceral leishmaniasis in India.","volume":"362","author":"Sundar","year":"2010","journal-title":"N Engl J Med"},{"key":"R5-12-20210205","first-page":"117","article-title":"A controlled, randomized nonblinded clinical trial to assess the efficacy of amphotericin B deoxycholate as compared to pentamidine for the treatment of antimony unresponsive visceral leishmaniasis cases in Bihar, India.","volume":"5","author":"Das","year":"2009","journal-title":"Ther Clin Risk Manag"},{"issue":"Suppl B","key":"R6-12-20210205","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1093\/jac\/28.suppl_B.49","article-title":"Pharmacology and toxicology of a liposomal formulation of amphotericin B (AmBisome) in rodents.","volume":"28","author":"Proffitt","year":"1991","journal-title":"J Antimicrob Chemother"},{"key":"R7-12-20210205","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1093\/infdis\/159.4.717","article-title":"Treatment of experimental invasive aspergillosis with novel amphotericin Bcholesterol-sulfate complexes.","volume":"159","author":"Patterson","year":"1989","journal-title":"J Infect Dis"},{"key":"R9-12-20210205","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1111\/j.1365-3156.2008.02144.x","article-title":"Drug regimens for visceral leishmaniasis in Mediterranean countries.","volume":"13","author":"Gradoni","year":"2008","journal-title":"Trop Med Int Health"},{"key":"R10-12-20210205","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1128\/AAC.35.4.615","article-title":"Amphotericin B lipid complex therapy of experimental fungal infections in mice.","volume":"35","author":"Clark","year":"1991","journal-title":"Antimicrob Agents Chemother"},{"key":"R11-12-20210205","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1128\/CMR.00061-07","article-title":"The relationship between leishmaniasis and AIDS: the second 10 years.","volume":"21","author":"Alvar","year":"2008","journal-title":"Clin Microbiol Rev"},{"key":"R12-12-20210205","doi-asserted-by":"crossref","first-page":"e764","DOI":"10.1371\/journal.pntd.0000764","article-title":"A curative immune profile one week after treatment of Indian kala-azar patients predicts success with a short-course liposomal amphotericin B therapy.","volume":"4","author":"Mondal","year":"2010","journal-title":"PLoS Negl Trop Dis"},{"key":"R13-12-20210205","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1517\/17425247.5.7.805","article-title":"Drug delivery systems against leishmaniasis Still an open question.","volume":"5","author":"Romero","year":"2008","journal-title":"Expert Opin Drug Deliv"},{"key":"R14-12-20210205","doi-asserted-by":"crossref","first-page":"71","DOI":"10.4103\/0022-3859.65276","article-title":"Liposomal amphotericin B (Fungisome) for the treatment of cryptococcal meningitis in HIVAIDS patients in India: a multicentric, randomized controlled trial.","volume":"56","author":"Jadhav","year":"2010","journal-title":"J Postgrad Med"},{"key":"R15-12-20210205","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/S0140-6736(10)62050-8","article-title":"Comparison of short-course multidrug treatment with standard therapy for visceral leishmaniasis in India: an open-label, noninferiority, randomised controlled trial.","volume":"377","author":"Sundar","year":"2011","journal-title":"Lancet"},{"key":"R16-12-20210205","doi-asserted-by":"crossref","first-page":"700","DOI":"10.4269\/ajtmh.2009.80.700","article-title":"Safety and efficacy of high-dose infusions of a preformed amphotericin B fat emulsion for treatment of Indian visceral leishmaniasis.","volume":"80","author":"Sundar","year":"2009","journal-title":"Am J Trop Med Hyg"},{"key":"R17-12-20210205","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1086\/500138","article-title":"Amphotericin B colloidal dispersion for the treatment of Indian visceral leishmaniasis.","volume":"42","author":"Sundar","year":"2006","journal-title":"Clin Infect Dis"},{"key":"R18-12-20210205","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1086\/507530","article-title":"Liposomal amphotericin B for the treatment of visceral leishmaniasis.","volume":"43","author":"Bern","year":"2006","journal-title":"Clin Infect Dis"},{"key":"R19-12-20210205","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1093\/jac\/dkm294","article-title":"Efficacy of liposomal amphotericin B for secondary prophylaxis of visceral leishmaniasis in HIV-infected patients.","volume":"60","author":"Molina","year":"2007","journal-title":"J Antimicrob Chemother"},{"key":"R20-12-20210205","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1086\/587899","article-title":"Concordant HIV infection and visceral leishmaniasis in Ethiopia: the influence of antiretroviral treatment and other factors on outcome.","volume":"46","author":"Ter Horst","year":"2008","journal-title":"Clin Infect Dis"},{"key":"R21-12-20210205","doi-asserted-by":"crossref","first-page":"e91","DOI":"10.1093\/cid\/cir521","article-title":"Liposomal amphotericin B for visceral leishmaniasis in human immunodeficiency virus-coinfected patients: 2-year treatment outcomes in Bihar, India.","volume":"53","author":"Sinha","year":"2011","journal-title":"Clin Infect Dis"},{"key":"R22-12-20210205","doi-asserted-by":"crossref","first-page":"2855","DOI":"10.2169\/internalmedicine.50.5617","article-title":"Visceral leishmaniasis mimicking as second line anti retroviral therapy failure.","volume":"50","author":"Yanamandra","year":"2011","journal-title":"Intern Med"},{"key":"R23-12-20210205","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.trstmh.2006.02.005","article-title":"Unresponsiveness to AmBisome in some Sudanese patients with kala-azar.","volume":"101","author":"Mueller","year":"2007","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"R24-12-20210205","doi-asserted-by":"crossref","first-page":"e152","DOI":"10.1093\/cid\/cir674","article-title":"Limited effectiveness of high-dose liposomal amphotericin B (AmBisome) for treatment of visceral leishmaniasis in an Ethiopian population with high HIV prevalence.","volume":"53","author":"Ritmeijer","year":"2011","journal-title":"Clin Infect Dis"},{"key":"R25-12-20210205","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1093\/jac\/dkh084","article-title":"Amphotericin B lipid complex versus no treatment in the secondary prophylaxis of visceral leishmaniasis in HIV-infected patients.","volume":"53","author":"Lopez-Velez","year":"2004","journal-title":"J Antimicrob Chemother"},{"key":"R26-12-20210205","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/j.ijantimicag.2008.02.007","article-title":"Diffuse cutaneous dissemination of visceral leishmaniasis during human immunodeficiency virus (HIV) infection, despite negligible immunodeficiency: repeated failure of liposomal amphotericin B administration, followed by successful long-term pentamidine and paromomycin administration.","volume":"31","author":"Manfredi","year":"2008","journal-title":"Int J Antimicrob Agents"},{"key":"R27-12-20210205","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1179\/136485905X514127","article-title":"Efficacy of liposomal amphotericin B (AmBisome) in the treatment of persistent postkala-azar dermal leishmaniasis (PKDL).","volume":"99","author":"Musa","year":"2005","journal-title":"Ann Trop Med Parasitol"},{"key":"R28-12-20210205","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1097\/QCO.0b013e32834a8ba1","article-title":"Recent advances in postkala-azar dermal leishmaniasis.","volume":"24","author":"Mondal","year":"2011","journal-title":"Curr Opin Infect Dis"},{"key":"R29-12-20210205","doi-asserted-by":"crossref","first-page":"715","DOI":"10.4269\/ajtmh.2008.79.715","article-title":"Post-Kala-Azar dermal leishmaniasis in an HIV-1-infected woman: recovery after amphotericin B following failure of oral miltefosine.","volume":"79","author":"Guffanti","year":"2008","journal-title":"Am J Trop Med Hyg"},{"key":"R30-12-20210205","doi-asserted-by":"crossref","first-page":"e25","DOI":"10.1016\/j.jinf.2005.09.015","article-title":"Successful treatment of postkala-azar dermal leishmaniasis (PKDL) in a HIV infected patient with multiple relapsing leishmaniasis from Western Europe.","volume":"53","author":"Rihl","year":"2006","journal-title":"J Infect"},{"key":"R31-12-20210205","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1111\/j.1365-3156.2009.02306.x","article-title":"Cost-effectiveness projections of single and combination therapies for visceral leishmaniasis in Bihar, India.","volume":"14","author":"Olliaro","year":"2009","journal-title":"Trop Med Int Health"},{"key":"R32-12-20210205","doi-asserted-by":"crossref","first-page":"e818","DOI":"10.1371\/journal.pntd.0000818","article-title":"Cost-effectiveness analysis of combination therapies for visceral leishmaniasis in the Indian subcontinent.","volume":"4","author":"Meheus","year":"2010","journal-title":"PLoS Negl Trop Dis"},{"key":"R34-12-20210205","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1128\/AAC.00870-07","article-title":"Comparison of the physicochemical, antifungal, and toxic properties of two liposomal amphotericin B products.","volume":"52","author":"Olson","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"R35-12-20210205","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/1744-8603-7-39","article-title":"A win-win solution A critical analysis of tiered pricing to improve access to medicines in developing countries.","volume":"7","author":"Moon","year":"2011","journal-title":"Global Health"},{"key":"R36-12-20210205","doi-asserted-by":"crossref","first-page":"e913","DOI":"10.1371\/journal.pntd.0000913","article-title":"A novel tropically stable oral amphotericin B formulation (iCo-010) exhibits efficacy against visceral Leishmaniasis in a murine model.","volume":"4","author":"Wasan","year":"2010","journal-title":"PLoS Negl Trop Dis"},{"key":"R37-12-20210205","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1080\/10611860701453836","article-title":"Antileishmanial efficacy of amphotericin B bearing emulsomes against experimental visceral leishmaniasis.","volume":"15","author":"Gupta","year":"2007","journal-title":"J Drug Target"},{"key":"R38-12-20210205","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1080\/10611860701195395","article-title":"Development and characterization of amphotericin B bearing emulsomes for passive and active macrophage targeting.","volume":"15","author":"Gupta","year":"2007","journal-title":"J Drug Target"},{"key":"R39-12-20210205","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1093\/jac\/dkn189","article-title":"Antileishmanial activity of nano-amphotericin B deoxycholate.","volume":"62","author":"Manandhar","year":"2008","journal-title":"J Antimicrob Chemother"},{"key":"R40-12-20210205","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1093\/jac\/dkr002","article-title":"Targeted killing of Leishmania donovani in vivo and in vitro with amphotericin B attached to functionalized carbon nanotubes.","volume":"66","author":"Prajapati","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"R41-12-20210205","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1093\/infdis\/jir735","article-title":"An oral formulation of amphotericin B attached to functionalized carbon nanotubes is an effective treatment for experimental visceral leishmaniasis.","volume":"205","author":"Prajapat","year":"2012","journal-title":"J Infect Dis"},{"key":"R42-12-20210205","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.ijantimicag.2008.10.013","article-title":"N-(2-hydroxypropyl)methacrylamide-amphotericin B (HPMA-AmB) copolymer conjugates as antileishmanial agents.","volume":"33","author":"Nicoletti","year":"2009","journal-title":"Int J Antimicrob Agents"},{"key":"R43-12-20210205","doi-asserted-by":"crossref","first-page":"2559","DOI":"10.1016\/j.bmc.2010.02.043","article-title":"Water-soluble polymer-drug conjugates for combination chemotherapy against visceral leishmaniasis.","volume":"18","author":"Nicoletti","year":"2010","journal-title":"Bioorg Med Chem"},{"key":"R47-12-20210205","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1080\/10611860400006596","article-title":"Amphotericin B molecular organization as an essential factor to improve activitytoxicity ratio in the treatment of visceral leishmaniasis.","volume":"12","author":"Sanchez-Brunete","year":"2004","journal-title":"J Drug Target"},{"key":"R48-12-20210205","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.ijpharm.2008.05.013","article-title":"Effect of aggregation state on the toxicity of different amphotericin B preparations.","volume":"361","author":"Espada","year":"2008","journal-title":"Int J Pharm"},{"key":"R49-12-20210205","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.ijpharm.2010.07.057","article-title":"A phospholipid-apolipoprotein A-I nanoparticle containing amphotericin B as a drug delivery platform with cell membrane protective properties.","volume":"399","author":"Burgess","year":"2010","journal-title":"Int J Pharm"},{"key":"R50-12-20210205","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1128\/AAC.50.4.1238-1244.2006","article-title":"Nanodisk-associated amphotericin B clears Leishmania major cutaneous infection in susceptible BALBc mice.","volume":"50","author":"Nelson","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"R51-12-20210205","first-page":"183","article-title":"Oral administration of solubilized amphotericin B.","volume":"265","author":"Kravetz","year":"1961","journal-title":"Med Intell"},{"key":"R52-12-20210205","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1128\/AAC.44.6.1598-1603.2000","article-title":"Mild heating of amphotericin B-desoxycholate: effects on ultrastructure, in vitro activity and toxicity, and therapeutic efficacy in severe candidiasis in leukopenic mice.","volume":"44","author":"van Etten","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"R53-12-20210205","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.2174\/138955709789878178","article-title":"Amphotericin B: from derivatives to covalent targeted conjugates.","volume":"9","author":"Sedlak","year":"2009","journal-title":"Mini Rev Med Chem"},{"key":"R54-12-20210205","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.nano.2008.03.007","article-title":"Development, characterization, and toxicity evaluation of amphotericin B-loaded gelatin nanoparticles.","volume":"4","author":"Nahar","year":"2008","journal-title":"Nanomedicine"},{"key":"R55-12-20210205","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.ijpharm.2006.08.013","article-title":"Formulation and characterization of amphotericin B-chitosan-dextran sulfate nanoparticles.","volume":"329","author":"Tiyaboonchai","year":"2007","journal-title":"Int J Pharm"},{"key":"R56-12-20210205","doi-asserted-by":"crossref","first-page":"2588","DOI":"10.1007\/s11095-009-9973-4","article-title":"Preparation, characterization and evaluation of targeting potential of amphotericin B-loaded engineered PLGA nanoparticles.","volume":"26","author":"Nahar","year":"2009","journal-title":"Pharm Res"},{"key":"R57-12-20210205","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1248\/bpb.29.1700","article-title":"Reduced renal toxicity of nanoparticular amphotericin B micelles prepared with partially benzylated poly-L-aspartic acid.","volume":"29","author":"Yoo","year":"2006","journal-title":"Biol Pharm Bull"},{"key":"R58-12-20210205","doi-asserted-by":"crossref","first-page":"9723","DOI":"10.1021\/la061408y","article-title":"Poly(ethylene glycol)-b-poly(epsilon-caprolactone) and PEG-phospholipid form stable mixed micelles in aqueous media.","volume":"22","author":"Vakil","year":"2007","journal-title":"Langmuir"},{"key":"R59-12-20210205","doi-asserted-by":"crossref","first-page":"5213","DOI":"10.1021\/la703570m","article-title":"Fast release of lipophilic agents from circulating PEG-PDLLA micelles revealed by in vivo forster resonance energy transfer imaging.","volume":"24","author":"Chen","year":"2008","journal-title":"Langmuir"},{"key":"R60-12-20210205","doi-asserted-by":"crossref","first-page":"3570","DOI":"10.1021\/la0531998","article-title":"Assessment of the integrity of poly(caprolactone)-b-poly(ethylene oxide) micelles under biological conditions: a fluorogenic-based approach.","volume":"22","author":"Savic","year":"2006","journal-title":"Langmuir"},{"key":"R61-12-20210205","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1016\/j.addr.2007.11.009","article-title":"Polymer-drug conjugates: recent development in clinical oncology.","volume":"60","author":"Li","year":"2008","journal-title":"Adv Drug Deliv Rev"},{"key":"R62-12-20210205","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1038\/sj.bjc.6604372","article-title":"Phase III trial comparing paclitaxel poliglumex vs docetaxel in the second-line treatment of nonsmall-cell lung cancer.","volume":"98","author":"Paz-Ares","year":"2008","journal-title":"Br J Cancer"},{"key":"R63-12-20210205","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/j.addr.2011.05.012","article-title":"Complement activation by carbon nanotubes.","volume":"63","author":"Rybak","year":"2011","journal-title":"Adv Drug Deliv Rev"}],"container-title":["Current Opinion in Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/QCO.0b013e328359eff2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T06:19:51Z","timestamp":1620973191000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00001432-201212000-00012"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,12]]},"references-count":57,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.1097\/qco.0b013e328359eff2","relation":{},"ISSN":["0951-7375"],"issn-type":[{"value":"0951-7375","type":"print"}],"subject":[],"published":{"date-parts":[[2012,12]]}}}